1. Academic Validation
  2. Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors

Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors

  • J Med Chem. 2009 Jun 11;52(11):3576-85. doi: 10.1021/jm900128w.
Allen J Duplantier 1 Stacey L Becker Michael J Bohanon Kris A Borzilleri Boris A Chrunyk James T Downs Lain-Yen Hu Ayman El-Kattan Larry C James Shenping Liu Jiemin Lu Noha Maklad Mahmoud N Mansour Scot Mente Mary A Piotrowski Subas M Sakya Susan Sheehan Stefanus J Steyn Christine A Strick Victoria A Williams Lei Zhang
Affiliations

Affiliation

  • 1 Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA. allen.j.duplantier@pfizer.com
Abstract

3-Hydroxyquinolin-2(1H)-one (2) was discovered by high throughput screening in a functional assay to be a potent inhibitor of human DAAO, and its binding affinity was confirmed in a Biacore assay. Cocrystallization of 2 with the human DAAO Enzyme defined the binding site and guided the design of new analogues. The SAR, pharmacokinetics, brain exposure, and effects on cerebellum D-serine are described. Subsequent evaluation against the rat DAAO Enzyme revealed a divergent SAR versus the human Enzyme and may explain the high exposures of drug necessary to achieve significant changes in rat or mouse cerebellum D-serine.

Figures